We’ll be attending the 2026 Great Lakes Drug Metabolism Discussion Group (GLDMDG) Annual Meeting, which brings together scientists focused on drug metabolism, pharmacokinetics (PK/DMPK) and bioanalytical strategy.

The meeting highlights emerging challenges in small molecule development, including complex matrices, metabolite identification and the need for high-quality data to support timely decision-making. Veloxity supports these efforts through high-quality LC-MS bioanalysis designed to deliver reliable PK/DMPK data with rapid turnaround times, helping teams move efficiently from discovery through clinical development.

We look forward to connecting with colleagues across the GLDMDG community and discussing approaches to accelerating bioanalysis without compromising data quality.

Attending GLDMDG? Reach out to connect with Jake and discuss small molecule bioanalysis and PK/DMPK challenges.